CARB-X, a global non-profit partnership, awarded Antabio with a $4.4 million grant to continue developing a novel antibiotic to treat Pseudomonas infections in cystic fibrosis patients. The money is the second installment from a grant awarded to Antabio in 2017.
Antabio receives $4.4M grant to continue development of CF antibiotic
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.